In this cohort of newly diagnosed T2DM subjects DR is associated with reduced β-cell responsiveness, resulting from β-cell failure rather than insulin resistance, leading to fasting and postprandial hyperglycaemia and hypoinsulinaemia. 
INTRODUCTION:
Diabetes Mellitus (DM) is a worldwide epidemic and recent estimates (1) indicate that the number of people living with DM is expected to rise from 366 million in 2011 to 552 million by 2030, with 90% having Type 2 DM (T2DM). A recent analysis reported that of individuals with DM there are approximately 93 million people (~35%) with Diabetic Retinopathy (DR), and 28 million with vision-threatening DR (~10%) worldwide (2) . In the United Kingdom, DR remains a leading cause of blindness in the working age population (3); thus early detection and treatment of modifiable risk factors known to influence its onset and progression is imperative. After 20 years of known DM duration approximately 40-60% of subjects with T2DM have some DR, with 10% of all T2DM subjects having developed sight threatening lesions related to proliferative DR and/or exudative maculopathy (4) .
Various risk factors have been associated with the development and progression of DR including hyperglycaemia (5) , duration of DM (5), hypertension and dyslipidaemia (6) (7) (8) . The UKPDS and DCCT, along with their 10 year follow-up, have demonstrated the benefits of early and sustained improvement in glycaemic control with respect to DR (9, 10).
Furthermore the UKPDS had shown that for every 1% decrease in HbA1c, there was a 37% risk reduction in microvascular complications in T2DM, predominantly DR (11) . Recently the Accord Eye Study Group has shown that intensive glucose and lipid lowering, but not intensive blood-pressure control, reduce the rate of progression of DR (12).
Further analysis of the DCCT study (13) reported that the total glycemic exposure (HbA1C and duration of diabetes) was able to explain 11% of the variation in retinopathy risk in the complete cohort, but other factors (e.g. environmental, genetic, glycemic variation and other measures of glycemia) could explain the remaining variation in risk on their own or through an intercorrelation with HbA1C.
Investigating the possible association between hyperglycaemia and the presence of DR has over the years involved measurement of various metabolic indices, predominantly HbA1C and/or fasting plasma glucose (11, 14) . In 2005 Shiraiwa et. al. showed that postprandial hyperglycaemia and postprandial hypoinsulinemia were possible predictors for incident DR in Japanese T2DM subjects who were not on insulin treatment (15) . The Diabetes Prevention Program (DPP), having studied subjects with impaired glucose tolerance and recent onset T2DM, found a higher baseline systolic blood pressure (SBP) and HbA1c amongst those with retinopathy, but found no difference in insulin secretion as estimated by the Corrected Insulin Response (CIR) (16) . In contrast a community based study in Taiwan demonstrated that both β-cell dysfunction and insulin resistance (IR) (both measured by the HOMA methodology)
were associated with DR in established T2DM patients (17) . Similarly, over the last decade, there have been other reports associating IR with DR (18) (19) (20) . However the relationship between β-cell function, glucose effectiveness (SG) and insulin sensitivity (SI) contributing to the level of fasting and postprandial dysglycaemia, with the presence of DR in newly diagnosed subjects with T2DM remains unreported.
The aim of this study was to examine the association between β-cell function and insulin sensitivity (SI) contributing to various fasting and postprandial glycaemic indices and the presence of DR in newly diagnosed and treatment naïve T2DM.
MATERIALS AND METHODS:

Subjects:
A total of 544 newly diagnosed, Caucasian subjects with T2DM were recruited into the study within 1-2 weeks after diagnosis of DM prior to any treatment between 1981 and 2007. The subjects were referred by primary care on clinical presentation and were diagnosed by either fasting glucose or Oral Glucose Tolerance Test (OGTT) according to WHO criteria (21). No formal dietetic or lifestyle advice or anti-diabetic medication was given prior to study enrollment.
Ethical approval was obtained from South Glamorgan/Bro Taf Local Research Ethics
Committee and all subjects gave informed consent.
Metabolic Tests:
All subjects were admitted at approximately 8am to an Investigation Unit following a 12-hour overnight fast and remained on bed rest throughout the morning of each of the study days.
Basic demographic data i.e. age, sex, height, weight and resting supine blood pressure were recorded and BMI calculated. Glycated haemoglobin and total cholesterol were measured.
All subjects (n=544; Group A) underwent a standardized Meal Tolerance Test (MTT). This involved consuming a 500-kcal meal over a 10 minute period (58% carbohydrate, 23% fat, and 19% protein) commencing at time 0 min (22) . Blood samples were taken from -30 to 240 minutes at 30 minute intervals, to determine plasma glucose, insulin, and C-peptide concentrations. The FSIVGTT consisted of baseline blood samples taken at -30, -15 and 0 minutes followed by a bolus of glucose (0.3g/kg body weight) given intravenously at 0 minute over a 2 minute period. Thereafter, blood samples were taken at one minute intervals over 10 minutes.
Following the intravenous bolus of insulin (Actrapid; Novo Nordisk, Bagsvaerd, Denmark) at a dose of 0.05 U/kg insulin given at 20 minutes (22) , blood samples were taken at frequent intervals up to 180 minutes. At each time point, measurements of plasma glucose and insulin were made.
For both the procedures (MTT and FSIVGTT), an indwelling intravenous cannula was inserted into an antecubital fossa vein and connected via a three-way tap to a slow-running saline infusion, to maintain the patency of the canula allowing for repeated blood sampling.
The technique was regularly checked to avoid any dilutional effect of the saline infusion.
Retinal Photography
Retinal images were obtained (Canon CR6-45NM) Non-Mydriatic Retinal Camera) through dilated pupils. Two 45° images were taken, one centred on the macula and one nasal field per eye. Classification of DR was based on the Diabetic Retinopathy Screening Service for Wales grading protocol, which is an enriched version of the UK National DR grading protocol (23) . The highest grade for both eyes used for classification. All grading was carried out by a senior grader from the Diabetic Retinopathy Screening Service for Wales (DRSSW) and a diabetologist trained to grade fundus photographs with the DRSSW grading protocol and any differences were reconciled by reference to a second diabetologist who was also trained to grade fundus photographs.
Assay methods:
Duing the metabolic tests blood was withdrawn and placed into tubes containing different anti-coagulants; fluoride/oxalate for glucose and lithium-heparin for measurement of C-peptide and specific insulin. Within approximately 10 minutes from collection, the blood tubes were spun in a refrigerated centrifuge for 5 minutes at approx 3000 rpm, and the plasma aliquoted into labelled tubes and stored frozen at -20°C until assay.
Glucose was measured by a glucose oxidase assay (YSI 2300, YSI, Hants, UK) and C-peptide and specific insulin by immunoassay (24) . The within-and between-assay coefficients of variation were 1.8% and 1.9%. 5.4% and 8.8%, and 4.1% and 8.8%, respectively for the glucose, C-peptide and insulin assays.
Glycated haemoglobin measurements were performed in a routine Haematology Department.
HbA1c measurements were determined using a high-performance liquid chromatography assay (TOSOH HLC-723 G7; Tosoh Corporation, Tokyo, Japan) (25) which was Diabetes Control and Complications Trial (DCCT) aligned and the laboratory participated in an external quality assessment scheme. The general assay performance for the HPLC method used had a reported coefficients of variation within and between assay of <2.0% (25) . HbA1 measured in the early part of the study by column chromatography was converted to HbA1c utilising the formula (HbA1c = 0.83HbA1 -0.54) (26).
Data analysis:
Glucose and insulin levels: Fasting plasma glucose (FPG) and fasting plasma insulin (FPI)
were measured. The postprandial plasma glucose (PPG) and plasma insulin (PPI) were represented by the 120 minute values and the areas under the curve AUC(0-240min) for plasma glucose and insulin over the 4 hour MTT period were calculated.
CPR program:
The CPR (Calculating Pancreatic Response) program was used to quantify pancreatic ß-cell responsiveness during the MTT. M0 (C-peptide response to fasting glucose) representing fasting prehepatic insulin secretion and M1 (C-peptide response to postprandial glucose) representing the increase in prehepatic insulin secretion in response to an increment in postprandial glucose were calculated (27) .
Minimal model analysis:
The minimal model analysis of FSIVGTT provided data on SI (ability of insulin to enhance the net glucose disappearance from plasma) and SG (ability of glucose to promote its own disposal and a marker of insulin-independent component of glucose tolerance) (28, 29) . The acute insulin response to glucose (AIRG) was the incremental area under the curve from 0-10 minutes during the FSIVGTT (30) . The Disposition Index (DI), representing the composite measure of insulin sensitivity and pancreatic ß-cell responsiveness, was calculated as DI = SI x AIRG (30).
HOMA calculation: HOMA-B, HOMA-S and HOMA-IR were calculated using fasting plasma glucose and specific insulin levels using the Homeostasis Model Assessment 
RESULTS:
Of the 544 subjects (Group A), (393 male and 151 female, 2.6:1) with a mean age of 54 (SD±10) years, 83.5% (454) had no evidence of DR and 16.5% (90) had evidence of DR at presentation. Of those with DR, the majority 84.4% (76) had lesions of BDR (including M1) and 15.6% (14) had PPDR; none had either exudative maculopathy or PDR. In the subgroup of 201 subjects (Group B) undergoing FSIVGTT in addition to MTT, 85% (171) subjects had no evidence of DR at presentation while 15% (30) had DR comprising 12.5% (25) with BDR and 2.5% (5) PPDR; none had either exudative maculopathy or PDR.
Baseline characteristics including age, weight, BMI, systolic and diastolic blood pressure, total cholesterol and HbA1c of the patients with DR and NDR in Groups A and B are detailed in Table 1 . At baseline, Group A subjects with DR had significantly lower body weight at diagnosis of DM (p=0.02) compared to those without DR. BMI was also lower in Group A and HbA1c was higher although both failed to reach statistical significance. There was no significant difference for the remaining baseline characteristics measured between those with or without DR. In Group B weight and BMI were lower in those with DR compared to those without DR however, this was not significant.
The metabolic variables measured during the MTT for Group A subjects with either DR or no DR are detailed in Table 2 . Those with DR had a lower estimated ß-cell responsiveness i.e. The baseline characteristics and the metabolic responses in Group B subjects with either NDR or DR who underwent FSIVGTT are detailed in Table 3 . Insulin sensitivity (SI) was not significantly different between the two groups however, the SG was significantly reduced in those with DR compared to those without DR (p=0.012). There was no difference in the AIRG and DI between those with or without DR.
In univariate logistic regression analysis postprandial glucose, AUCGlucose (0-240min), postprandial insulin, AUCInsulin (0-240min), M0, HOMA-B and SG were significantly associated with the presence of DR (Table 4) .
Factors associated with DR in multivariate logistic regression analyses are detailed in (Table   4 when adjusted for the mentioned variables (age, gender, BMI, systolic blood pressure and total cholesterol) though the HbA1c was higher in subjects with DR. Each 1 mmol/L increase in fasting and postprandial glucose was associated with a two-fold increase the risk of DR.
Also each 1 pmol/L decrease in fasting and postptandial insulin was associated with increased risk of DR by 24% and 34% respectively.
In the multivariate logistic regression models once adjusted for glycaemia (using either HbA1c/FPG/PPG) in addition to those mentioned above (age, gender, BMI, systolic blood pressure and total cholesterol), ß-cell responsiveness or ß-cell function were the most significant risk factors for the presence of DR at diagnosis of diabetes. (Table 5) .
DISCUSSION:
Our findings have shown that the presence of DR is associated with a reduced fasting β-cell responsiveness and function. This has resulted in hyperglycaemia in both the fasting and postprandial state, concurrent with fasting and postprandial insulinopaenia. In addition the insulin-independent component of glucose tolerance was reduced and independently associated with the presence of DR at diagnosis.
In this study, whilst employing both the CPR program (27) were treated with lifestyle modifications and/or oral hypoglycaemic agents. They observed that those subjects with better preserved β-cell function were less likely to have DR. The UKPDS has reported that the severity of retinopathy at diagnosis of T2DM was related in both sexes to higher fasting plasma glucose levels, higher systolic and diastolic blood pressure, lower serum insulin levels, and reduced beta-cell function (32) . The association between fasting β-cell dysfunction and DR in established T2DM patients as reported by Tung et al (17) is also present in our newly-diagnosed, treatment naïve, T2DM subjects. This contrasts with the DPP study involving newly diagnosed T2DM subjects, where no difference in insulin secretion estimated by the CIR was found (16) . Glucose effectiveness (SG) represents the capacity of glucose, per se, to enhance glucose cellular uptake and to suppress endogenous glucose production and has been reported to be an important determinant of glucose metabolism (35). The glucose transporter protein GLUT-1 is widely distributed on the plasma membrane of various body tissues contributing an important role in insulin-independent glucose uptake (36, 37) . Thus, in the presence of significant β-cell dysfunction and resultant insulinopaenia, a relatively poor SG will further worsen glycaemia. This might explain our findings, where the newly diagnosed T2DM subjects with worse SG are more likely to present with DR.
Our study therefore demonstrates the significant contributions of β-cell dysfunction, fasting and postprandial hyperglycaemia/insulinopaenia and reduced glucose effectiveness. Thus it adds to the evidence base of co-contributory factors towards development of diabetic complications. Several epidemiological studies have confirmed the association between hyperglycaemia and the development of late diabetic complications (9, 38) . However most of the previous studies have employed the time-averaged mean levels of glycaemia measurement of HbA1c as a measure for glycaemic status. Over the last decade there has been increasing recognition that HbA1c is not a complete expression of the degree of hyperglycaemia and that other aspects of dysglycaemia contribute to the increased risk of diabetic complications and HbA1c was reported to account for 11% of the risk of retinopathy in the DCCT (13) . Recent research has also suggested that postprandial glucose levels and glucose variability, may confer additional risk for the development of micro-and macrovasular diabetic complications (39, 40) .
In our study we measured insulin sensitivity both by the MINMOD program (following FSIVGTT) and HOMA (following MTT) and found no difference between T2DM subjects presenting with DR compared to those without DR at the time of diagnosis. Our study cohort differs from previous reports because it comprised of only newly diagnosed, treatment naïve participants with T2DM, and thus lacked the confounding effects of therapeutic interventions.
By contrast, other cross-sectional studies have associated insulin sensitivity (assessed by euglycemic clamp) with the presence or severity of DR (18) (19) (20) . The numbers of subjects and controls in those studies were modest and the subjects recruited had established T2DM that was being treated with variety of hypoglycaemic agents, both oral and insulin. It is therefore unclear whether the association that they found was entirely independent of the underlying confounders such as duration and treatment modalities of DM. Thus in our subjects presenting with DR there is no significant contribution from diminished insulin sensitivity/resistance at time of clinical diagnosis.
The DPP reported that more than 12% of subjects with T2DM had DR within approximately 3 years of diagnosis (16) . 16 .5% of our subjects with newly diagnosed T2DM, who presented with DR were studied within 1-2 weeks of diagnosis, possibly indicating a slightly longer pre-clinical period in our cohort. Whilst our study is limited by its cross sectional design that makes it difficult to confirm a cause and effect relationship, the strength of our study lies in the recruitment of subjects at clinical diagnosis. Thus, we were able to rule out confounding factors such as known duration of DM and treatment modalities, however we do acknowledge that duration prior to clinical diagnosis may have been substantial. It also presents a detailed analysis of the metabolic response of a T2DM subject emanating from a diminished fasting functional β-cell state, resulting in both fasting and postprandial dysglycaemia leading to DR but not being affected by an element of insulin resistance/sensitivity.
To summarise, in newly diagnosed treatment-naïve T2DM subjects, the presence of DR is associated with relatively worse functional status of both the insulin dependent (as manifested by lower β-cell responsiveness with resultant relative insulinopaenia) and insulin independent (as manifested by reduced SG) components of glucose tolerance. Thus in this cohort of newly diagnosed T2DM subjects, DR is associated with reduced β-cell responsiveness resulting from β-cell failure rather than insulin resistance leading to a fasting and postprandial state of hyperglycaemia and hypoinsulinaemia. 1b) Fasting (M0) and Post-prandial (M1) β-cell responsiveness during MTT in subjects with NDR and those with DR at diagnosis of T2DM
